2025년 11월 26일 16:20

With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?

An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lac ...

생명공학제약조사분석

2025년 10월 30일 09:00

Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®

As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live - j ...

제약사업 확장

2025년 9월 12일 15:20

Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec

Ferring Pharmaceuticals Co., Ltd. announced that the PMDA has accepted the NDA for nadofaragene firadenovec for review, following submission on Au ...

제약인증

2025년 7월 2일 17:08

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta

Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/da ...

생명공학임상시험연구개발

2025년 4월 22일 10:20

Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1

Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firad ...

임상시험제약연구개발

2025년 4월 9일 15:28

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin

Ferring achieved total revenues of €2.3 billion in 2024, an increase of 7% over the previous year at actual exchange rates (AER) and 8% at constan ...

제약실적

2024년 10월 4일 16:50

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intrav ...

제약인증

2024년 10월 2일 09:42

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-t ...

임상시험제약연구개발

2024년 4월 9일 14:28

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Ferring today published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at ...

제약실적

2023년 12월 11일 16:00

Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration ...

제약제휴

2023년 8월 24일 15:45

Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)

Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales ...

제약연구개발

2023년 6월 22일 14:25

Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new ...

제약인사

2023년 6월 16일 14:16

Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CH ...

제약투자

2023년 5월 10일 10:15

Four Analyses of Data for REBYOTA™ (fecal microbiota, live - jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (f ...

제약전시

2023년 5월 10일 10:15

최초로 FDA가 승인한 재발성 클로스트리듐 디피실 감염 예방 위한 마이크로비옴 기반 치료제 레비오타의 데이터 분석 4가지, 2023년 DDW서 발표

페링 제약회사는 오늘 Digestive Disease Week®(DDW 2023)에서 레비오타(REBYOTA™: 분변 생미생물총 - jslm)에 대한 3건의 구두 발표와 1건의 포스터 발표가 있음을 알렸으며, 이 ...

제약전시

2023년 4월 18일 17:07

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health

Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health. BioInnovation Institu ...

제약생명공학제휴

2023년 3월 15일 14:40

Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine

Today, an oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific So ...

제약의료와 병원조사분석

2023년 3월 15일 14:40

페링, 태평양 생식의학 협회 회의에서 Rekovelle®에 대한 최초의 전향적·다국적·실제 연구 초록 발표

오늘 최초의 허가 후 4상 실제 연구인 프로파일(PROFILE)의 오럴 포스터가 호주에서 열린 제13회 태평양 생식 의학 협회(Pacific Society for Reproductive Medicine, PSRM) 2023 ...

제약조사분석

2022년 12월 2일 09:20

Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) - A Novel First-in-Class Microbiota-Based Live Biotherapeutic

Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first ...

제약의료와 병원연구개발

2022년 12월 2일 09:20

페링, 레비요타(REBYOTA®) 미국 FDA 승인 획득… 업계 최초의 미생물군 기반 생균 치료제

페링제약(Ferring Pharmaceuticals)이 미국 식품의약국(FDA)이 레비요타(REBYOTA®, 대변 미생물군, live-jslm)를 승인했다고 발표했다. 레비요타는 업계 최초의 새로운 미생물군 ...

제약의료와 병원연구개발

2022년 10월 25일 16:55

Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic

Ferring Pharmaceuticals today announced the presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting of seven ...

제약의학조사분석

2022년 10월 25일 16:55

페링, ACG 2022서 연구용 미생물군 기반 생물 치료제 RBX2660 관련 7가지 새로운 분석 발표

페링제약(Ferring Pharmaceuticals)이 2022 미국소화기학회(ACG) 연례 과학 회의에서 연구용 미생물군 기반 생물 치료제인 RBX2660이 항생제 치료 후 재발성 C. 디피실리(CDI) 감 ...

제약의학조사분석

2022년 10월 21일 11:00

Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660, Its Investigational Microbiota-based Live Biotherapeutic

Ferring Pharmaceuticals today announced the presentation of two subgroup analyses at Infectious Disease Week (IDWeek) 2022 that further characteri ...

제약의료와 병원조사분석

2022년 10월 21일 11:00

페링, IDWeek 2022서 연구용 미생물군 기반 생물 치료제 RBX2660의 HRQL·안전성·효능 데이터 평가한 새로운 하위 그룹 분석 발표

페링제약(Ferring Pharmaceuticals)이 2022년 감염병 주간(IDWeek)에서 2개의 하위 그룹 분석 관련 프레젠테이션을 진행했다. 이번 프레젠테이션에는 항생제 치료 후 C. 디피실리 ...

제약의료와 병원조사분석

2022년 9월 23일 13:30

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Ad ...

제약의료와 병원연구개발

 전체 기업